Chamberlin M E, Ubagai T, Mudd S H, Levy H L, Chou J Y
Heritable Disorders Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892, USA.
Am J Hum Genet. 1997 Mar;60(3):540-6.
Methionine adenosyltransferase (MAT) I/III deficiency, characterized by isolated persistent hypermethioninemia, is caused by mutations in the MAT1A gene encoding MAT(alpha)1, the subunit of major hepatic enzymes MAT I ([alpha1]4) and III([alpha1]2). We have characterized 10 MAT1A mutations in MAT I/III-deficient individuals and shown that the associated hypermethioninemic phenotype was inherited as an autosomal recessive trait. However, dominant inheritance of hypermethioninemia, also hypothesized to be caused by MAT I/III deficiency, has been reported in two families. Here we show that the only mutation uncovered in one of these families, G, is a G-->A transition at nt 791 in exon VII of one MAT1A allele that converts an arginine at position 264 to a histidine (R264H). This single allelic R264H mutation was subsequently identified in two hypermethioninemic individuals in an additional family, C. Family C members were also found to inherit hypermethioninemia in a dominant fashion, and the available affected members analyzed carried the single allelic R264H mutation. Substitution of R-264 with histidine (R264H, the naturally occurring mutant), leucine (R264L), aspartic acid (R264D), or glutamic acid (R264E) greatly reduced MAT activity and severely impaired the ability of the MAT(alpha)1 subunits to form homodimers essential for optimal catalytic activity. On the other hand, when lysine was substituted for R-264 (R264K), the mutant alpha1 subunit was able to form dimers that retain significant MAT activity, suggesting that amino acid 264 is involved in intersubunit salt-bridge formation. Cotransfection studies show that R264/R264H MAT(alpha)1 heterodimers are enzymatically inactive, thus providing an explanation for the R264H-mediated dominant inheritance of hypermethioninemia.
甲硫氨酸腺苷转移酶(MAT)I/III缺乏症,其特征为单纯持续性高甲硫氨酸血症,由编码MAT(α)1的MAT1A基因突变引起,MAT(α)1是主要肝脏酶MAT I([α1]4)和III([α1]2)的亚基。我们已对MAT I/III缺乏症个体中的10个MAT1A突变进行了特征分析,并表明相关的高甲硫氨酸血症表型以常染色体隐性性状遗传。然而,在两个家族中报告了高甲硫氨酸血症的显性遗传,也推测是由MAT I/III缺乏症引起的。在此我们表明,在其中一个家族中发现的唯一突变G,是一个MAT1A等位基因外显子VII中第791位核苷酸处的G→A转换,该转换将第264位的精氨酸转变为组氨酸(R264H)。随后在另一个家族C的两名高甲硫氨酸血症个体中鉴定出了这个单等位基因R264H突变。还发现家族C成员以显性方式遗传高甲硫氨酸血症,并且所分析的现有患病成员携带单等位基因R264H突变。用组氨酸(R264H,天然存在的突变体)、亮氨酸(R264L)、天冬氨酸(R264D)或谷氨酸(R264E)替代R-264会大大降低MAT活性,并严重损害MAT(α)1亚基形成对最佳催化活性至关重要的同型二聚体的能力。另一方面,当用赖氨酸替代R-264(R264K)时,突变的α1亚基能够形成保留显著MAT活性的二聚体,这表明第264位氨基酸参与亚基间盐桥的形成。共转染研究表明,R264/R264H MAT(α)1异源二聚体无酶活性,从而为R264H介导的高甲硫氨酸血症的显性遗传提供了解释。